Navigation Links
IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
Date:9/12/2012

MENLO PARK, Calif., Sept. 12, 2012 /PRNewswire/ -- IncellDx, Inc. announced today that it has initiated a large-scale study called SLIQUE (study to compare slideless and liquid-based Pap smears). The study is being conducted in partnership with BioReference Laboratories, Inc. (NASDAQ: BRLI) and is expected to take anywhere from three to six months.  Over 10,000 samples will be used to compare the performance of OncoTect 3Dx™ technology with liquid-based cytology (ThinPrep™ and SurePath™) methods. IncellDx recently presented on OncoTect 3Dx™ at the Eurogin Conference (http://www.eurogin.com/2012) and this study represents the next step in commercializing the technology.

Current Pap smear technology is slide-based and requires manual review of each slide by specially trained technicians, increasing cost and reducing throughput. OncoTect 3Dx™ uses a proprietary flow cytometry-based technology to improve and automate the process. "Liquid-based cytology represents an approximately $5 billion market opportunity for IncellDx," said Bruce Patterson, MD, CEO and Founder of IncellDx. "Our OncoTect 3Dx™ technology has the potential to increase the sensitivity and specificity of the liquid-based Pap smear while it simultaneously reduces the cost and turnaround time."

"This is a very interesting technology that opens up new horizons as we continue to innovate in the women's health space," said Marc Grodman, MD, CEO of BioReference Laboratories and Chairman of the Board of IncellDx. "We expect that OncoTect 3Dx™ has the potential to be disruptive in the marketplace both here in the United States and anywhere in the world where cytology resources are scarce."

IncellDx and BioReference expect the study to provide sufficient data to plan a FDA trial for the OncoTect 3Dx™ technology.

More information about OncoTect® and OncoTect 3Dx™:

About IncellDx, Inc.  
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more information, please visit www.incelldx.com.

ThinPrep™ is a trademark owned by Hologic and SurePath™ is a trademark owned by BD.


'/>"/>
SOURCE IncellDx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 Shire ... that the U.S. Food and Drug Administration (FDA) has ... New Drug Application (NDA) for SHP465, a long-acting, triple-bead, ... a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The ... around June 20, 2017, the designated Prescription Drug User ...
(Date:1/19/2017)... CAMBRIDGE, England , January 19, 2017 ... MedImmune and Otsuka in the Milner Therapeutics Consortium   ... academic scientists in Cambridge   ... Inc. (NYSE: PFE ) as a partner ... join the Consortium, which enables the efficient transfer of ...
(Date:1/19/2017)... January 19, 2017 While ... serious about reducing the FDA,s regulatory strictness as ... the medical drug industry, many of the leading ... clinical trials and development of advanced drug treatments ... with recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology:
(Date:1/20/2017)... , ... January 20, 2017 , ... "TransFlare 4K Mystique ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have ...
(Date:1/20/2017)... ... ... Chocolate Biscuit”: a biographical account following a man who went on to support his country ... Ivey, born in Lynn Haven, Florida and at the age of 5, his family moved ... he joined the Navy and got married right out of boot camp. , He ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Journey to Christmas:” a beautiful and enchanting ... of published author, Kimberly Cordoves, a mother of three in Oklahoma City, and a devoted ... idea of writing a book has been in the back of my mind for years, ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for ... in four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate in ... APMs are an important part of the Administration’s effort to build a system that ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... With the cold weather here, many people ... Snow blowers are efficient when clearing large amounts of snow, but they can be dangerous ... the U.S. Consumer Product Safety Commission for the proper use of snow blowers:, ...
Breaking Medicine News(10 mins):